SCHEMBL158309

SCHEMBL158309

N=C(N)NOC(=O)c1ccccc1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 5/20 0.68
ALDH1A1 P00352 4/20 0.68
MAPT P10636 4/20 0.68
POLB P06746 2/20 0.68
TSHR P16473 3/20 0.54
F2 P00734 2/20 0.52
LMNA P02545 1/20 0.52
TDP1 Q9NUW8 4/20 0.48
PKM P14618 3/20 0.48
BLM P54132 2/20 0.48
RECQL P46063 2/20 0.48
L3MBTL1 Q9Y468 2/20 0.48
CYP3A4 P08684 2/20 0.48
F10 P00742 1/20 0.48
F12 P00748 1/20 0.48
F7 P08709 1/20 0.48
F3 P13726 1/20 0.48
PARP1 P09874 1/20 0.48
CYP2C19 P33261 1/20 0.48
PMP22 Q01453 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL27483793 0.98 KMT2A (0.66) KMT2AALDH1A1MAPTPOLBTSHR
SCHEMBL7555577 0.89 ALDH1A1 (0.52) KMT2AALDH1A1MAPTPOLBTSHR
SCHEMBL8641757 0.86 ALDH1A1 (0.50) KMT2AALDH1A1MAPTPOLBF2
SCHEMBL6269137 0.85 ALDH1A1 (0.70) KMT2AALDH1A1MAPTPOLBTSHR
SCHEMBL9699705 0.85 ALDH1A1 (0.59) KMT2AALDH1A1MAPTPOLBTSHR
SCHEMBL4907232 0.85 ALDH1A1 (0.76) KMT2AALDH1A1MAPTPOLBTSHR
Hydrochloric Acid SCHEMBL29271905 0.83 ALDH1A1 (0.58) KMT2AALDH1A1MAPTPOLBTSHR
SCHEMBL9150262 0.82 ALDH1A1 (0.66) KMT2AALDH1A1MAPTPOLBTSHR
SCHEMBL12348301 0.82 KMT2A (0.66) KMT2AALDH1A1MAPTPOLBTSHR
SCHEMBL184146 0.81 ALDH1A1 (0.44) KMT2AALDH1A1MAPTPOLBTSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 295 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12398222-B2 Flame-retardant antimicrobial agent, preparation method therefor and use thereof, and flame-retardant antimicrobial thermoplastic resin composition CHINA PETROLEUM & CHEMICAL CORPORATION (CN) 2025-08-26 US claimed
EP-4053177-B1 FLAME-RETARDANT ANTIMICROBIAL AGENT, PREPARATION METHOD THEREFOR AND USE THEREOF, AND FLAME-RETARDANT ANTIMICROBIAL THERMOPLASTIC RESIN COMPOSITION CHINA PETROLEUM & CHEM CORP (CN) 2025-01-22 EP claimed
CN-118724761-A Preparation method of novel guanidine benzoate derivatives and application of guanidine benzoate derivatives in pancreatitis 天津理工大学 2024-10-01 CN claimed
CN-115260646-B Flame-retardant antibacterial thermoplastic resin composition and preparation method and application thereof 中国石油化工股份有限公司 2024-08-06 CN claimed
CN-115260506-B Flame-retardant antibacterial agent and preparation method and application thereof 中国石油化工股份有限公司 2024-06-04 CN claimed
CN-115230271-B High-barrier anti-adhesion composite film and preparation method and application thereof 中国石油化工股份有限公司 2024-05-07 CN claimed
CN-114427124-B Antibacterial flame-retardant polypropylene fiber composition, preparation method thereof, fiber and non-woven fabric 中国石油化工股份有限公司 2024-02-13 CN claimed
CN-114341211-B Flame-retardant antibacterial agent, preparation method and application thereof, and flame-retardant antibacterial thermoplastic resin composition 中国石油化工股份有限公司 2023-11-21 CN claimed
CN-117004199-A Antibacterial glass fiber reinforced polyglycolic acid composite material and preparation method and application thereof 中国石油化工股份有限公司 2023-11-07 CN claimed
CN-114474923-B Polyethylene rotational molding body and preparation method and application thereof 中国石油化工股份有限公司 2023-10-10 CN claimed
WO-2009002913-A1 USE OF CREATINE COMPOUNDS TO TREAT DERMATITIS AVICENA GROUP, INC. (US) 2008-12-31 WO claimed
EP-1198230-A4 USE OF CREATINE OR CREATINE COMPOUNDS FOR SKIN PRESERVATION ENERDERMICS INC (US) 2004-06-16 EP claimed
US-20040054006-A1 Use of creatine or creatine analogs for the prevention and treatment of Transmissible Spongiform Encephalopathies KADDURAH-DAOUK RIMA (US) 2004-03-18 US claimed
US-20020049253-A1 Use of creatine or creatine compounds for skin preservation AVICENA GROUP, INC. 2002-04-25 US claimed
EP-1198230-A1 USE OF CREATINE OR CREATINE COMPOUNDS FOR SKIN PRESERVATION Avicena Group, Inc. (US) 2002-04-24 EP claimed
US-6242491-B1 ADMINISTERING CREATINE PHOSPHATE FOR WRINKLE, AGING, AND SOLAR RADIATION RESISTANCE AND AS FREE RADICAL SCAVENGER LIBRARY PHARMA, INC. 2001-06-05 US claimed
WO-2001000212-A1 USE OF CREATINE OR CREATINE ANALOGS FOR THE PREVENTION AND TREATMENT OF TRANSMISSIBLE SPONGIFORM ENCEPHALOPATHIES AVICENA GROUP, INC. (US) 2001-01-04 WO claimed
WO-2001000203-A1 USE OF CREATINE OR CREATINE COMPOUNDS FOR SKIN PRESERVATION AVICENA GROUP, INC. (US) 2001-01-04 WO claimed
US-4703014-A Karl-Fischer reagent and process for the determination of water MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 1987-10-27 US claimed
EP-0229370-A1 Guanidinobenzoic ester derivative, a process for preparing same and pharmaceutical compositions containing same Eisai Co., Ltd. (JP) 1987-07-22 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020049253-A1 Use of creatine or creatine compounds for skin preservation PC, CKMT1A; CKMT1B, CHEK1 KMT2A 2210/4885ALDH1A1 2904/4885MAPT 3406/4885
US-20040054006-A1 Use of creatine or creatine analogs for the prevention and treatment of Transmissible Spongiform Encephalopathies PRNP, CKMT1A; CKMT1B, PRPS1 KMT2A 2152/4885ALDH1A1 3272/4885MAPT 861/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.